retatrutide fda status 2025 Trial of next-gen weight-loss drug brings it one step closer to approval Retatrutide (LY3437943) — Dosing, Side

Luo et al

7,8-benzoflavone)

By promoting weight loss, tesofensine may indirectly contribute to improving insulin sensitivity in individuals with obesity or overweight

Author Contributions Concept and design: Sara Humaida, Kamar Manzalji, Naheel Seyam, Lolwa Al-Masalmani Acquisition, analysis, or interpretation of data: Sara Humaida, Kamar Manzalji, Naheel Seyam, Lolwa Al-Masalmani Drafting of the manuscript: Sara Humaida, Kamar Manzalji, Naheel Seyam, Lolwa Al-Masalmani Critical review of the manuscript for important intellectual content: Sara Humaida, Kamar Manzalji, Naheel Seyam, Lolwa Al-Masalmani References 1.GLP-1 receptor agonists and the risk of thyroid cancer

Considerations and future directions The central histaminergic system has received considerable interest for its ability to regulate energy balance, however, many unanswered questions remain